Lupin Limited (LUPIN) - Total Assets
Based on the latest financial reports, Lupin Limited (LUPIN) holds total assets worth Rs383.65 Billion INR (≈ $4.15 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lupin Limited - Total Assets Trend (2004–2026)
This chart illustrates how Lupin Limited's total assets have evolved over time, based on quarterly financial data. Also see how much is Lupin Limited worth for the company's overall valuation and market capitalisation.
Lupin Limited - Asset Composition Analysis
Current Asset Composition (March 2026)
Lupin Limited's total assets of Rs383.65 Billion consist of 62.6% current assets and 37.4% non-current assets. Review LUPIN total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 14.7% |
| Accounts Receivable | Rs66.07 Billion | 17.2% |
| Inventory | Rs60.83 Billion | 15.9% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs32.07 Billion | 8.4% |
| Goodwill | Rs26.59 Billion | 6.9% |
Asset Composition Trend (2004–2026)
This chart illustrates how Lupin Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See LUPIN live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lupin Limited's current assets represent 62.6% of total assets in 2026, an increase from 56.0% in 2004.
- Cash Position: Cash and equivalents constituted 14.7% of total assets in 2026, up from 2.5% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 17.2% of total assets.
Lupin Limited Competitors by Total Assets
Key competitors of Lupin Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
Lupin Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.90 | 1.87 | 1.66 |
| Quick Ratio | 1.42 | 1.26 | 1.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs113.76 Billion | Rs78.37 Billion | Rs55.50 Billion |
Lupin Limited - Advanced Valuation Insights
This section examines the relationship between Lupin Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.68 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 31.4% |
| Total Assets | Rs383.65 Billion |
| Market Capitalization | $10.20 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Lupin Limited's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Lupin Limited's assets grew by 31.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Lupin Limited (2004–2026)
The table below shows the annual total assets of Lupin Limited from 2004 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs383.65 Billion ≈ $4.15 Billion |
+31.36% |
| 2025-03-31 | Rs292.05 Billion ≈ $3.16 Billion |
+21.70% |
| 2024-03-31 | Rs239.97 Billion ≈ $2.60 Billion |
+4.54% |
| 2023-03-31 | Rs229.56 Billion ≈ $2.48 Billion |
+5.20% |
| 2022-03-31 | Rs218.21 Billion ≈ $2.36 Billion |
-7.58% |
| 2021-03-31 | Rs236.10 Billion ≈ $2.55 Billion |
-5.50% |
| 2020-03-31 | Rs249.84 Billion ≈ $2.70 Billion |
-10.61% |
| 2019-03-31 | Rs279.49 Billion ≈ $3.02 Billion |
+6.25% |
| 2018-03-31 | Rs263.05 Billion ≈ $2.84 Billion |
-1.13% |
| 2017-03-31 | Rs266.07 Billion ≈ $2.88 Billion |
+17.60% |
| 2016-03-31 | Rs226.25 Billion ≈ $2.45 Billion |
+72.21% |
| 2015-03-31 | Rs131.38 Billion ≈ $1.42 Billion |
+28.73% |
| 2014-03-31 | Rs102.06 Billion ≈ $1.10 Billion |
+14.50% |
| 2013-03-31 | Rs89.14 Billion ≈ $964.00 Million |
+11.67% |
| 2012-03-31 | Rs79.82 Billion ≈ $863.25 Million |
+30.34% |
| 2011-03-31 | Rs61.24 Billion ≈ $662.33 Million |
+20.43% |
| 2010-03-31 | Rs50.85 Billion ≈ $549.97 Million |
+23.01% |
| 2009-03-31 | Rs41.34 Billion ≈ $447.09 Million |
+22.90% |
| 2008-03-31 | Rs33.64 Billion ≈ $363.78 Million |
+48.64% |
| 2007-03-31 | Rs22.63 Billion ≈ $244.73 Million |
+12.71% |
| 2006-03-31 | Rs20.08 Billion ≈ $217.13 Million |
+48.25% |
| 2005-03-31 | Rs13.54 Billion ≈ $146.46 Million |
+10.10% |
| 2004-03-31 | Rs12.30 Billion ≈ $133.02 Million |
-- |
About Lupin Limited
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic … Read more